COMP <GO>
DFTX vs TRLV // RSI-14 & 200D SMA MOMENTUM
Definium Therapeutics Inc. (NASDAQ) VS. Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE) • 15-METRIC TALLY: DFTX 4
— TRLV 5
▲ RSI-14 & 200D SMA MOMENTUM LEADER: DFTX
LAST: $37.96 (-0.37%) • MKT CAP: $5.10B
rsi-technicals
55.4
LAST: $10.60 (-0.19%) • MKT CAP: $2.04B
rsi-technicals
43.3
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DFTX VS. TRLV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DFTX | TRLV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 60.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.20% | 12.80% | -45.00 | TRLV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 9.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.84% | 11.20% | -15.04 | TRLV | /fcf-yield <GO> |
| Operating Margin | -11.60% | 12.10% | -23.70 | TRLV | /operating-margins <GO> |
| Net Profit Margin | -12.90% | -9.90% | -3.00 | TRLV | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | -0.40% | +5.90 | DFTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 1.12 | +24.88 | DFTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | TRLV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 55.4 | 43.3 | +12.13 | DFTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.10B | $2.04B | $3.06B | DFTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DFTX REV | TRLV REV | DFTX GROSS % | TRLV GROSS % | DFTX FCF | TRLV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $1.18B | — | 60.2% | -$131.6M | $228.6M |
| FY 2024 | $0 | $1.19B | — | 60.3% | -$79.1M | $148.9M |
| FY 2023 | $0 | $1.13B | — | — | -$64.4M | $201.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DFTX // BETA 1.08
TRLV // BETA —